6-Hydroxy-L-DOPA
Suppliers
Names
[ CAS No. ]:
27244-64-0
[ Name ]:
6-Hydroxy-L-DOPA
[Synonym ]:
L-Hydroxydopa
2,4,5-trihydroxyphenyl-L-alanine
2,4,5-trihydroxy-L-phenylalanine
2,5-Dihydroxy-L-tyrosine
2,5-Dihydroxy-L-tyrosine 3-(2,4,5-Trihydroxyphenyl)-L-alanine
L-6-Hydroxydopa
(2S)-2-amino-3-(2,4,5-trihydroxyphenyl)propanoic acid
2,4,5,-trihydroxyphenylalanine
2,4,5-Trihydroxyphenylalanine,L
6-OH-DOPA
L-2,4,5-Trihydroxyphenylalanine
6-Hydroxydopa
Chemical & Physical Properties
[ Density]:
1.606g/cm3
[ Boiling Point ]:
515.2ºC at 760mmHg
[ Molecular Formula ]:
C9H11NO5
[ Molecular Weight ]:
213.19
[ Flash Point ]:
265.4ºC
[ Exact Mass ]:
213.06400
[ PSA ]:
124.01000
[ LogP ]:
0.45810
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- AY7640000
- CHEMICAL NAME :
- Alanine, 3-(2,4,5-trihydroxyphenyl)-, L-
- CAS REGISTRY NUMBER :
- 27244-64-0
- LAST UPDATED :
- 199206
- DATA ITEMS CITED :
- 1
- MOLECULAR FORMULA :
- C9-H11-N-O5
- MOLECULAR WEIGHT :
- 213.21
- WISWESSER LINE NOTATION :
- QVYZ1R BQ DQ EQ
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 100 mg/kg
- SEX/DURATION :
- female 17 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - biochemical and metabolic
- REFERENCE :
- LIFSAK Life Sciences. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1-8, 1962-69; V.14- 1974- Volume(issue)/page/year: 17,987,1975
Safety Information
[ Hazard Codes ]:
Xi
[ RIDADR ]:
NONH for all modes of transport
[ HS Code ]:
2922509090
Customs
[ HS Code ]: 2922509090
[ Summary ]:
2922509090. other amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
Articles
FEBS Lett. 380(1-2) , 183-7, (1996)
Resonance Raman spectra were obtained of the free radical site in substrate reduced anaerobic samples of pea seedling copper amine oxidase (PSAO). The spectra differ significantly from those reported ...
Synapse 61 , 606-614, (2007)
Evidence obtained in rodent and primate models of Parkinson's disease (PD) and preliminary clinical trials, indicates that adenosine A(2A) receptor antagonists might represent a promising nondopaminer...
Neurosignals 15(5) , 238-48, (2006)
Overactivity of the glutamatergic system is suggested to be closely related to the onset and pathogenesis of Parkinson's disease. Vesicular glutamate transporters (VGLUT1, T2 and T3) are a group of gl...